Latest news
Debiopharm Investment SA acquires famous Parisian restaurants in partnership with GROUPE BERTRAND and Galiena Capital
Debiopharm International SA announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective…
Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID
Debiopharm International SA has won its Patent Infringement Suit for Elplat® against Nippon Kayaku Co., Ltd.
Debiopharm International SA and EORTC announce a collaboration to investigate Triptorelin for treatment of Salivary Gland Cancers
Debiopharm International SA and Arbor Pharmaceuticals, LLC announce their US commercialization partnership for Triptorelin in Central Precocious Puberty
United Laboratories Inc. and Debiopharm International SA announce the launch of Pamorelin® LA in the Philippines
EMA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer